Filing Analysis
Veru Inc. entered into a clinical supply agreement with Novo Nordisk A/S on June 2, 2026, for the Phase 2b PLATEAU clinical study. Novo Nordisk will provide Wegovy® at no charge for the study in exchange for clinical insights and a right of first negotiation for future combined commercialization.
🚩 Red Flags
- The 'Forward-Looking Statements' section explicitly mentions the company's need to obtain financing to 'enable us to continue as a going concern'.
- The Supply Agreement can be terminated by Novo Nordisk for convenience upon 60 days' prior notice.
📋 Key Facts
- Agreement date: June 2, 2026.
- Novo Nordisk will supply Wegovy® (semaglutide) at no charge for the Phase 2b PLATEAU study.
- Veru is solely responsible for conducting and sponsoring the study.
- Veru granted Novo Nordisk a 'right of first negotiation' for future development or licensing of enobosarm in combination with Novo Nordisk GLP-1 products.
- Veru retains full global development and commercialization rights to enobosarm.
Veru Inc. reported its financial results for the fiscal second quarter and six months ended March 31, 2026. The information was furnished via a press release as part of a routine quarterly earnings disclosure.
📋 Key Facts
- Filing date: May 13, 2026
- Reporting period: Fiscal quarter and six months ended March 31, 2026
- Disclosed under Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains the full earnings press release
Veru Inc. reported the results of its 2026 Annual Meeting, where shareholders approved a significant expansion of the 2018 Equity Incentive Plan. The amendment more than doubles the authorized shares for issuance and substantially increases individual award limits for both employees and directors.
🚩 Red Flags
- Significant potential dilution: The 125% increase in authorized shares for the equity plan (3.25 million additional shares) is substantial for a micro-cap company.
- The annual limit for awards to non-employee directors was increased 12-fold from 10,000 to 120,000 shares.
📋 Key Facts
- Authorized shares in the 2018 Equity Incentive Plan increased from 2,600,000 to 5,850,000 shares.
- Annual award limit for participants other than non-employee directors increased from 100,000 to 750,000 shares.
- Annual award limit for non-employee directors increased from 10,000 to 120,000 shares.
- Shareholders ratified Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
- All six director nominees, including CEO Mitchell S. Steiner, were re-elected to the Board.